gene editing

Researchers report that epigenetic editing can silence hepatitis B virus, effectively banishing it rather than merely suppressing it. The approach targets the virus's gene activity without cutting DNA, offering a possible route toward a functional cure for a infection that affects hundreds of millions and is a leading cause of liver cancer. Readers are discussing the promise and hurdles before human use.

Researchers report engineering a compact CRISPR enzyme with a 60-fold increase in gene-editing power. The mini enzyme, if validated, could make gene therapies more efficient with smaller delivery vehicles, a key limitation in current CRISPR treatments. Coverage in the biology community highlights the size-and-strength tradeoff as a notable advance for therapeutic and research applications.

A one-time CRISPR gene-editing treatment reportedly cut LDL, or "bad," cholesterol roughly in half, with effects lasting a full year. The finding suggests gene editing could one day offer a durable alternative to daily statins for people at risk of heart disease. Coverage is drawing attention to the potential of permanent, single-dose therapies for one of the world's leading causes of death, though longer and larger trials will be needed before wide use.

Reports say epigenetic editing — altering gene activity without changing DNA sequence — is moving closer to clinical application as the bioengineering tools behind it mature. Unlike CRISPR-style gene cutting, epigenetic approaches aim to switch genes on or off reversibly, and researchers see growing potential for treating disease with fewer permanent risks. The field is watching which tools and trials will translate first.